

CURRICULUM VITAE

Dr. Marco Sorio

Personal data

Date of birth:

Place of birth:

Citizenship : Italian

Work address: Azienda Ospedaliera Universitaria Integrata di Verona, Sezione di Ematologia e Centro Trapianto Midollo Osseo, Dipartimento di Medicina - Divisione di Ematologia

Policlinico G.B. Rossi

Piazzale L.A. Scuro, 10

37134, Verona- Italy

phone: 045 8124647, fax: 045 8027488

E-mail: marco.sorio@univr.it

Education

1994 Medical Doctor degree, University of Verona, Verona, Italy

1999 National Board of Hematology, University of Verona, Verona, Italy

Medical Licence: Mantova - Italy, 1995: number 2448

Professional Record, Main work and Experience in the Research Area

- Hematology training, Department of Hematology, University of Verona, Italy 1995-1999
- Fellowship, Department of Hematology and Oncology Unit, City Hospital of Mantova, Italy, 1999-2001
- Fellowship, Department of Hematology and Bone Marrow Transplantation, University of Verona, Italy, 2001-2004
- Staff Member, Department of Hematology and Bone Marrow Transplantation, University of Verona, Italy, 2004-present.

Publications: some original contributions to international journals and abstracts

Papers and Abstracts:

- High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).
Ladetto M, Corradini P, Vallet S, Benedetti F, Vitolo U, Martelli M, Brugiatelli M, Coser P, Perrotti A, Majolino I, Fioritoni G, Morandi S, Musso M, Zambello R, Chisesi T, Di Renzo N, Vivaldi P, De Crescenzo A, Gallamini A, Salvi F, Santini G, Boccomini C, **Sorio M**, Astolfi M, Drandi D, Pileri A, Tarella C. Blood. 2002 Sep 1;100(5):1559-65.
- Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H.
Scambi C, La Verde V, De Franceschi L, Barausse G, Poli F, Benedetti F, **Sorio M**, Deriu F, Roncada P, Bortolami O, Turrini F, Caramaschi P, Stranieri C, Bambara LM, Biasi D. PLoS One. 2010 Aug 13;5(8):e12162. doi: 10.1371/journal.pone.0012162.
- Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.
Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola M, **Sorio M**, Caracciolo D, Gianni AM, Rambaldi A. J Clin Oncol. 2011 Mar 1;29(7):814-24. doi: 10.1200/JCO.2010.28.9777. Epub 2010 Dec 28.

- The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series.
Tecchio C, Mosna F, Andreini A, Paoli L, Di Bella R, de Sabata D, **Sorio M**, Pizzolo G, Benedetti F. Leuk Lymphoma. 2013 May;54(5):1020-7. doi: 10.3109/10428194.2012.733877. Epub 2013 Feb 19.
- The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study.
Scambi C, Ugolini S, Jokiranta TS, De Franceschi L, Bortolami O, La Verde V, Guarini P, Caramaschi P, Ravagnani V, Martignoni G, Colato C, Pedron S, Benedetti F, **Sorio M**, Poli F, Biasi D. PLoS One. 2015 Feb 6;10(2):e0114856. doi: 10.1371/journal.pone.0114856. eCollection 2015
- Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study. Bedogni A, Bettini G, Bedogni G, Basso D, Gatti D, Valisena S, Brunello A, **Sorio M**, Berno T, Giannini S, Navaglia F, Plebani M, Nocini PF, Blandamura S, Saia G, Bertoldo F.J Craniomaxillofac Surg. 2019 Aug;47(8):1203-1208. doi: 10.1016/j.jcms.2019.03.007. Epub 2019 Mar 13.
- Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy.
Mariatto S, Tecchio C, **Sorio M**, Bertolasi L, Turatti M, Tozzi MC, Benedetti F, Cavaletti G, Monaco S, Ferrari S.. Leuk Lymphoma. 2019 Nov;60(11):2806-2809. doi: 10.1080/10428194.2019.1605068. Epub 2019 May 6. No abstract available

Last GCP training: "ICH GCP E6 (R2)" – 05 Oct 2020

Clinical Trial Experience

Several years of experience in conducting phase II and III clinical trials in hematology according ICH GCP Guidelines.

Marco Sorio, MD

14/6/21

